Theralase Technologies Inc. (TSXV: TLT)

Market Cap	61.95M
Revenue (ttm)	986.60K
Net Income (ttm)	-4.33M
Shares Out	247.78M
EPS (ttm)	-0.02
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	287,012
Open	0.275
Previous Close	0.270
Day's Range	0.230 - 0.275
52-Week Range	0.140 - 0.380
Beta	1.36
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 29, 2024

About Theralase Technologies

Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research and development of light activated photo dynamic compounds (PDCs) and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. It also designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions. In addition, the company develop...

• Industry: Medical Devices
• Sector: Healthcare
• CEO: Roger Dumoulin-White
• Employees: 20
• Stock Exchange: TSX Venture Exchange
• Ticker Symbol: TLT

Financial Performance

In 2023, Theralase Technologies's revenue was 1.07 million, a decrease of -6.00% compared to the previous year's 1.14 million. Losses were -4.57 million, -12.69% less than in 2022.